The purpose of the survey is to provide the Canadian Cancer Survivor Network (CCSN) with insights and perspectives about living with and managing advanced stages of prostate cancer from patients and caregivers in order to complete a patient evidence submission for a new medication for metastatic castration-resistant prostate cancer called Xtandi (enzalutamide). This new medication will soon be going through a national cancer drug review process that invites patient groups like CCSN to prepare and send in submissions so that patients and caregivers like you can be heard. Please join us and have your voice included in this important submission process.

The survey will be available starting now and remain open until March 8, 2013.

Thank you for your participation.

Question Title

* 1. What are the symptoms or problems you experience with advanced prostate cancer that affect your day-to-day living and quality of life?

Question Title

* 2. Which of these symptoms are the most important to control. Please pick your top 5:

Question Title

* 3. What therapies/treatments are you currently using to treat your disease?

Question Title

* 4. How effective have the therapies/treatments listed in question 3 been at controlling common aspects of advanced prostate cancer? Please check all that apply.

  Very effective Somewhat effective Not very effective Not effective at all
Docetaxel (Taxotere)
Cabazitaxel (Jevtana)
Mitoxantrone
Abiraterone acetate (Zytiga)
Radiation therapy
Other hormone therapy

Question Title

* 5. What are the common adverse effects you have experienced and are some more difficult to manage than others?

Question Title

* 6. Have you had issues accessing current therapy?

Question Title

* 7. Are there any needs in your current therapy that are not yet being met?

Question Title

* 8. Expectations of a New Drug – No Experience with enzalutamide (Xtandi)

Please complete these questions if you have not been treated with enzalutamide (Xtandi)

Based on the needs in question 7, how much of an improvement would be needed from the new drug to make it better than current treatment? Please describe:

T